Clinical Trials Logo

Recurrent Non-Hodgkin Lymphoma clinical trials

View clinical trials related to Recurrent Non-Hodgkin Lymphoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05077527 Not yet recruiting - HIV Infection Clinical Trials

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

Start date: April 15, 2024
Phase: Phase 1
Study type: Interventional

This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or not responded to treatment (refractory). T cells are infection fighting blood cells that can kill tumor cells. Axicabtagene ciloleucel consists of genetically modified T cells, modified to recognize CD-19, a protein on the surface of cancer cells. These CD-19-specific T cells may help the body's immune system identify and kill CD-19-positive B-cell non-Hodgkin lymphoma cells.